Filtered By:
Condition: Heart Disease
Vaccination: Vaccines

This page shows you your search results in order of date.

Order by Relevance | Date

Total 71 results found since Jan 2013.

Joint Prevalence of Influenza Preventive Behaviors Among Adults-United States, 2020
CONCLUSIONS: The overall joint prevalence was 8.5% (95% CI, 8.0-9.0). Prevalence was lower among older persons (vs younger); Hispanic and non-Hispanic Black persons (vs non-Hispanic White); current and former smokers (vs never smokers); postpartum women (vs neither pregnant nor postpartum); and those with a history of coronary heart disease, hypertension, stroke, diabetes, and chronic obstructive pulmonary disease (vs not having those respective condition). In addition to recommending annual vaccination, primary care providers might encourage sufficient sleep and adequate physical activity-especially among patients who hav...
Source: Primary Care - August 12, 2023 Category: Primary Care Authors: Bryant J Webber Anne G Wheaton Peng-Jun Lu Geoffrey P Whitfield Source Type: research

COVID-19 ’ s Impact on Heart Health Still Confounds Doctors
(ST. LOUIS) — Firefighter and paramedic Mike Camilleri once had no trouble hauling heavy gear up ladders. Now battling long COVID, he gingerly steps onto a treadmill to learn how his heart handles a simple walk. “This is, like, not a tough-guy test so don’t fake it,” warned Beth Hughes, a physical therapist at Washington University in St. Louis. [time-brightcove not-tgx=”true”] Somehow, a mild case of COVID-19 set off a chain reaction that eventually left Camilleri with dangerous blood pressure spikes, a heartbeat that raced with slight exertion, and episodes of intense chest pain...
Source: TIME: Health - August 10, 2023 Category: Consumer Health News Authors: Lauran Needgaard/ Associated Press Tags: Uncategorized COVID-19 healthscienceclimate wire Source Type: news

Protective effect of vaccination on the risk of cardiovascular disease after SARS-CoV-2 infection
ConclusionAlthough COVID-19 increased the CVD risk, the inverse association in the risk of CVDs according to vaccine doses was significant in a dose –response manner. Our findings suggest that ≥ second doses of the COVID-19 vaccine prevent the risk of CVDs after SARS-CoV-2 infection.Graphical abstractIn 2,146,130 infected adults ( ≥ 20 years), the inverse association in the short-term risk of cardiovascular diseases, including coronary heart disease and stroke, according to vaccine doses received was significant in a dose–response manner.
Source: Clinical Research in Cardiology - July 31, 2023 Category: Cardiology Source Type: research

Influenza vaccination and cardiovascular events in patients with ischaemic heart disease and heart failure: A meta ‐analysis
ConclusionIn this meta-analysis of available RCTs in patients at high cardiovascular risk, influenza vaccination was associated with a reduced incidence of cardiovascular events, cardiovascular death and all-cause death as compared to placebo or no treatment.
Source: European Journal of Heart Failure - June 28, 2023 Category: Cardiology Authors: Daniel Modin, Mats Christian H øjbjerg Lassen, Brian Claggett, Niklas Dyrby Johansen, Maryam Keshtkar‐Jahromi, Kristoffer Grundtvig Skaarup, Joshua Nealon, Jacob A. Udell, Orly Vardeny, Scott D. Solomon, Gunnar Gislason, Tor Biering‐Søren Tags: Research Article Source Type: research

Impact of influenza, herpes zoster, and pneumococcal vaccinations on the incidence of cardiovascular events in subjects aged over 65  years: a systematic review
Geroscience. 2023 Jun 3. doi: 10.1007/s11357-023-00807-4. Online ahead of print.ABSTRACTThis systematic review aims to summarize the impact of vaccination against influenza, shingles, and pneumococcus on the incidence on the risk of cardiovascular events in the elderly. This protocol was developed in accordance with PRISMA guidelines. We conducted a literature search and identified all relevant articles published regarding the matter up to September 2022. We retrieved 38 studies (influenza vaccine = 33, pneumococcal vaccine = 5, and zoster vaccine = 2). A total of 28 and 2 studies have shown that influenza and pneumococcal...
Source: Herpes - June 3, 2023 Category: Infectious Diseases Authors: Alexandra Addario Thomas C élarier Bienvenu Bongue Nathalie Barth Ga ëtan Gavazzi Elisabeth Botelho-Nevers Source Type: research

ERLEADA ® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
HORSHAM, Pa., April 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States. The introduction of the 240mg tablet provides the first-and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).With two strengths available, healthcare professionals will have the flexibility to...
Source: Johnson and Johnson - April 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Stewardship for Science and Vaccines
Despite the success of vaccines in the modern world, including the rapid development of the COVID-19 vaccine, my state is now experiencing a large measles outbreak and a decline in immunization rates. At the turn of the century, the Centers for Disease Control and Prevention published “Ten Great Public Health Achievements” of the twentieth century in the United States.1 Vaccination topped the list, a national and global success story. Other achievements included improvements in motor-vehicle safety, control of infectious diseases, safer workplaces, decline in deaths from coro nary heart disease and stroke, safer and he...
Source: Pediatric Clinics of North America - February 24, 2023 Category: Pediatrics Authors: Tina L. Cheng Tags: Foreword Source Type: research

How COVID-19 Changes the Heart —Even After the Virus Is Gone
While COVID-19’s effects on the lungs and respiratory system are well known, there is growing research suggesting that the virus is also affecting the heart, with potentially lasting effects. In a presentation at the annual meeting of the Biophysical Society, an international biophysics scientific group, Dr. Andrew Marks, chair of the department of physiology at Columbia University, and his colleagues reported on changes in the heart tissue of COVID-19 patients who had died from the disease, some of whom also had a history of heart conditions. The team conducted autopsy analyses and found a range of abnormalities, pa...
Source: TIME: Health - February 18, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news